Early health technology assessments in pharmacogenomics: a case example in cardiovascular drugs

TY - JOUR

T1 - Early health technology assessments in pharmacogenomics

T2 - a case example in cardiovascular drugs

AU - Geenen, Joost W.

AU - Baranova, Ekaterina V.

AU - Asselbergs, Folkert W.

AU - de Boer, Anthonius

AU - Vreman, Rick A.

AU - Palmer, Colin N. A.

AU - Maitland-van der Zee, Anke Hilse

AU - Hövels, Anke M.

AU - PREDICTION-ADR Consortium

N1 - No funding info

PY - 2017/8

Y1 - 2017/8

N2 - Aim: To assess the required characteristics (cost, sensitivity and specificity) of a pharmacogenomic test for being a cost-effective prevention of angiotensin-converting enzyme inhibitors induced angioedema. Furthermore, we assessed the influence of only testing high-risk populations.Materials & Methods: A decision tree was used.Results: With a willingness-to-pay threshold of €20,000 and €80,000 per quality adjusted life year, a 100% sensitive and specific test may have a maximum cost of €1.30 and €1.95, respectively. When only genotyping high-risk populations, the maximum test price would be €5.03 and €7.55, respectively.Conclusion: This theoretical pharmacogenomic test is only cost-effective at high specificity, high sensitivity and a low price. Only testing high-risk populations yields more realistic maximum test prices for cost-effectiveness of the intervention.

AB - Aim: To assess the required characteristics (cost, sensitivity and specificity) of a pharmacogenomic test for being a cost-effective prevention of angiotensin-converting enzyme inhibitors induced angioedema. Furthermore, we assessed the influence of only testing high-risk populations.Materials & Methods: A decision tree was used.Results: With a willingness-to-pay threshold of €20,000 and €80,000 per quality adjusted life year, a 100% sensitive and specific test may have a maximum cost of €1.30 and €1.95, respectively. When only genotyping high-risk populations, the maximum test price would be €5.03 and €7.55, respectively.Conclusion: This theoretical pharmacogenomic test is only cost-effective at high specificity, high sensitivity and a low price. Only testing high-risk populations yields more realistic maximum test prices for cost-effectiveness of the intervention.

KW - Journal article

KW - Adverse drug reactions

KW - Angioedema

KW - ACE inhibitors ACE inhibitor induced angioedema

KW - Cardiovascular drugs

KW - Cost–effectiveness

KW - Health technology assessment

KW - Pharmacogenomic test

U2 - 10.2217/pgs-2017-0063

DO - 10.2217/pgs-2017-0063

M3 - Article

C2 - 28745583

SN - 1462-2416

VL - 18

JO - Pharmacogenomics

JF - Pharmacogenomics

IS - 12

ER -